Wednesday, September 30, 2020
Home Life Style Health & Fitness US Approves Drug 'Balversa' as First Targeted Therapy for Bladder Cancer

US Approves Drug ‘Balversa’ as First Targeted Therapy for Bladder Cancer

Bladder cancer is the sixth most common cancer in the United States, with the FGFR alterations present in about one in five patients

Johnson & Johnson’s drug Balversa won U.S. approval as the first targeted therapy for advanced bladder cancer, the Food and Drug Administration
announced Friday.

The list price of the drug, known chemically as erdafitinib, will range between $10,080 and $22,680 for a 28-day supply, depending on the dosage, J&J said.

Balversa is the first approved drug in a class known as FGFR inhibitors that targets growth factor receptors involved in cell growth and division.

bladder cancer
The list price of the drug, known chemically as erdafitinib, will range between $10,080 and $22,680 for a 28-day supply, depending on the dosage, J&J said. Pixabay

The drug is approved for use in patients whose cancer has progressed during or after chemotherapy and have specific genetic alterations known as FGFR3 or FGFR2. Patients will be selected for therapy with Balversa using an FDA-approved companion diagnostic device that will identify the genetic  mutations, the agency said.

Bladder cancer is the sixth most common cancer in the United States, with the FGFR alterations present in about one in five patients.

“We’re in an era of more personalized or precision medicine, and the ability to target cancer treatment to a patient’s specific genetic mutation or biomarker is becoming the standard,” Richard Pazdur, head of the FDA’s oncology products division, said in a statement.

 

bladder cancer
Balversa is the first approved drug in a class known as FGFR inhibitors that targets growth factor receptors involved in cell growth and division. Pixabay

J&J shares closed up 0.5 percent at $135.98. Shares of Incyte Corp., which is also developing a FGFR inhibitor, closed down 2 percent at $79.40.

ALSO READ: Prostrate Medicines Likely to Increase Risk of Type-2 Diabetes

The approval was based on a small 87-patient trial in which about a third of subjects experienced tumor shrinkage. The median duration before disease progression was 5.4 months.

Common side effects of the drug include high phosphate levels, mouth sores and fatigue. The drug may cause serious eye problems, including inflamed eyes, the FDA said. (VOA)

STAY CONNECTED

19,134FansLike
362FollowersFollow
1,778FollowersFollow

Most Popular

Being a Father in Real Life, One Understands The Equation: Kunal Kemmu on Playing a Parent On Screen

Actor Kunal Kemmu says fatherhood in real life has helped him portray a father on screen. "It obviously helps because being a father in real...

UN Agencies Urge People to Reduce Food Loss

At the global event marking the first International Day of Awareness of Food Loss and Waste, the UN Food and Agriculture Organisation (FAO), the...

Airborne Transmission of Covid-19 Spreads More Quickly Indoors: Study

A new research adds to the growing body of evidence that airborne transmission of Covid-19 spreads more quickly in enclosed spaces. Researchers were able to...

Jewelry: An Investment and a Sentiment

After a tough six months of pandemic (and continuing) wherein most of us were resigned to our homes and restrained ourselves from socializing, finally...

Is There Greater Risk of Heart Disease to Men than Women?

Over the years, multiple researchers have concluded that heart disease impacts men and women differently. It has been noted that in the younger age...

Knowing the Basics of Your Sneaker Shoes

Sneaker Shoes have taken over the world and how! Understandably so, because who would do not want to sport footwear that is not only...

Fusion Taking Over in Indian Kitchens

Owing to the pandemic, food consumption has become a cautious habit and people are highly conscious of what they are eating and where it...

Sean Toy Provides Rudimentary Overview of Nutrition

Nutrition makes up the second half of the exercise equation, with work and effort being the other, yet many who are committed to consistently...

Recent Comments